Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on SI-BONE, Lowers Price Target to $37

Needham analyst David Saxon maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $42 to $37.

byBenzinga Newsdesk

August 3, 2021

1 minute read

Needham analyst David Saxon maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $42 to $37.

FDA Places Clinical Hold On Foghorn Therapeutics’ Early-Stage Blood Cancer Trial

By Vandana Singh

Today, 5:47 AM

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc’s (NASDAQ:FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory…

FHTX

Agilysys Raises FY23 Revenue To $195M-$198M Vs $194.4M Est

By Benzinga Newsdesk

Today, 5:47 AM

Fiscal 2023 Outlook The Company announced it is raising full-year fiscal 2023 revenue guidance to be $195 to $198 million, inclusive of close to 30% subscription revenue growth

AGYS

Untapped Value in the Small-Business Market? This Communications Company Says Yes

By Austin Willson

Today, 5:47 AM

Photo by Leon on Unsplash

DTGI

News

Nebula Brands Emerges as Star to Watch in Global Constellation of Amazon Aggregators

By The Bamboo Works

Today, 5:47 AM

Key Takeaways: Nebula Brands has announced a major new fundraising, bolstering its place as China’s top player in an emerging global group of Amazon aggregators

AMZN

Needham Maintains Buy on SI-BONE, Lowers Price Target to $37

Related Posts

FDA Places Clinical Hold On Foghorn Therapeutics’ Early-Stage Blood Cancer Trial

Agilysys Raises FY23 Revenue To $195M-$198M Vs $194.4M Est

Untapped Value in the Small-Business Market? This Communications Company Says Yes

Nebula Brands Emerges as Star to Watch in Global Constellation of Amazon Aggregators